Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 64.85M P/E - EPS this Y - Ern Qtrly Grth -
Income -19.5M Forward P/E -12.89 EPS next Y - 50D Avg Chg -11.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 3.31 EPS next 5Y - 52W High Chg -54.00%
Recommedations 2.00 Quick Ratio 3.68 Shares Outstanding 100.31M 52W Low Chg 29.00%
Insider Own 38.04% ROA -44.64% Shares Float 61.41M Beta 0.23
Inst Own 0.78% ROE -90.40% Shares Shorted/Prior 257.78K/365.78K Price 0.64
Gross Margin - Profit Margin - Avg. Volume 125,445 Target Price -
Oper. Margin - Earnings Date Apr 25 Volume 21,381 Change 2.33%
About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Tiziana Life Sciences Ltd News
04/25/24 Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
04/23/24 Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
04/22/24 Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
04/19/24 Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
04/18/24 Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
04/11/24 Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
03/05/24 Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
01/09/24 TLSA: First Phase II SPMS Patient Dosed
01/08/24 Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
01/05/24 Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
01/05/24 Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
12/19/23 Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
12/04/23 Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
11/30/23 Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
11/01/23 Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
10/20/23 TLSA: Six Month SPMS Results
10/18/23 Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
10/17/23 Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
10/16/23 Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
10/13/23 Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
TLSA Chatroom

User Image Iceman89 Posted - 1 hour ago

$TLSA Teplizumab was approved based on a phase 2 study of 76 participants. Foralumabs study has 54 participants + 30 in the future from the Expanded Access program. Could FDA give a green light, when no safety issues are found? Teplizumab had additional safety data for hundreds of patients, but its efficacy was more questionable compared to Foralumab, which has supportive PET-imaging data. So far 0 toxicity issues with Foralumab and there is no approved treatment + Dr. Weiner is a known name in the MS community to push this through the FDA.

User Image Iceman89 Posted - 16 hours ago

$TLSA Amazing summary. https://x.com/DrTarunSinghal/status/1784051622018183558

User Image AOCashMoney Posted - 1 day ago

$TLSA LMAO and the bleeding begins. Delisting or RS? Both are tragic for a stock.

User Image ShareOurSuccess Posted - 1 day ago

$TLSA Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program 70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-up

User Image rp6577 Posted - 2 days ago

$TLSA great summary. Truly a very exciting prospect $XBI $LABU

User Image Iceman89 Posted - 2 days ago

$TLSA I put down a short summary of my investment thesis as this recent data got me excited (again). Not a financial advice, but I'm putting my money where my mouth is. Anything else to add to it? I tried to keep it short and sweet.

User Image Iceman89 Posted - 2 days ago

$TLSA The latest news about the improvement in the white matter of the brain is really good, because it showed efficacy in 5 of 6 patients and the efficacy range is very robust at 28% to 48% and a 36% median reduction in White Matter Z-scores compared to baseline. It was known before from the earlier patients data, that it has an effect on white matter, but these good results just confirm that Foralum REALLY works. FDA will LOVE this, when it grants an approval!

User Image TheTradeXchange Posted - 2 days ago

$TLSA Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab

User Image Stock_Titan Posted - 2 days ago

$TLSA Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab https://www.stocktitan.net/news/TLSA/tiziana-life-sciences-reports-positive-3-month-neuroimaging-scores-b13fxzfhnghe.html

User Image rp6577 Posted - 2 days ago

$TLSA really starting to get some traction. Data always wins out in the end

User Image ShortingTheTrend Posted - 2 days ago

$TLSA 🚨🚨🚨

User Image ShareOurSuccess Posted - 2 days ago

$TLSA Multiple Sclerosis News Today The clinically meaningful improvement in fatigue levels seen in seven out of ten patients, as well as the stabilization or improvements in other key clinical outcome measures that were seen in all patients, underscores the potential of Tiziana’s investigational therapy to address this critical unmet need

User Image ShareOurSuccess Posted - 2 days ago

$TLSA Multiple Sclerosis News Today Foralumab found to ease fatigue in SPMS patients in access program Use of nasal spray reduced levels after 6 months in 7 of 10 patients in EAP. That’s according to early findings from the EAP — a program that enables patients with serious or life-threatening conditions to have access to an experimental therapy outside of clinical trials

User Image Sam2025 Posted - 2 days ago

$TLSA Is this going to hit $1. Seems like it is just stuck in the 70's.

User Image greedandfear101 Posted - 2 days ago

$TSLL why would you buy $TLSA when you can buy $TSLL ??

User Image ShareOurSuccess Posted - 3 days ago

$TLSA Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program 70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months of Follow-up

User Image AOCashMoney Posted - 3 days ago

$TLSA ummm… you see the SP right? This is about to RS for compliance or DELIST. No one in their right mind would buy a stock before a reverse split.

User Image StockMarketTV Posted - 3 days ago

Tesla $TLSA is finding support at a major inflection point.

User Image win_condition Posted - 3 days ago

$NVDA $TLSA

User Image rp6577 Posted - 3 days ago

$TLSA 😂 he’s turning into a buy signal

User Image WallStreetBuyDip Posted - 3 days ago

How do you make a trade? $TLSA are you the type to trade momentum or the type to buy the dip for a reversal trade? Will trade TLSA like how I did for these tickers shown here. These only show 4 trades of 100+ others The key is to buy when H% is low for a reversal trade. Review the Step-by-Step on chart.

User Image raoulpal Posted - 3 days ago

It never ceases to amaze me the emotions that $TLSA and $NVDA create in the bulls and the bears. It's a war of philosophies and worldviews, and not really about the stocks themselves, obviously. I think the world is going to split between those who want technology to prevail and those who don't and want things to stay the same, or even revert to a past memory of simpler times. It's the same divide we see in those who invest in tech and those that look for "value". However, the results have shown that over the last 30 years, technology has outperformed any other strategy ...over time. But this is clearly not about results. This divide is likely going to be larger than the current "left vs right" as The Exponential Age begins to accelerate and this divide may well define the next 30 years. I don't see how it will be stopped and thus don't see how it won't create more emotional conflict, if you let it. To be fair, not everyone who dislikes TSLA or NVDA stock is driven by philosophy.

User Image AlphaAndOmega Posted - 4 days ago

$TLSA Elon: ‘More affordable Tesla possibly later in 2024, certainly early in 2025’

User Image AOCashMoney Posted - 4 days ago

$TLSA these pumpers have been saying this for the last few years here. It gets close to a dollar and then it tanks back to $.50. If you buy at any price now, you will be back holding for years to come. They will do nothing with Foralumab. They hyped it for Covid, and nothing happened. They continue to hype it and nothing happens.

User Image GeraldK75 Posted - 4 days ago

$TLSA They are doing so much, holding a bag no problem here.

User Image He8moreThanHecanChew Posted - 4 days ago

$TSLA $tlsa is down , dyslexia play

User Image Dnmr1 Posted - 4 days ago

$TLSA this will be targeted by big pharma for at least a 20 bag price if results are this good so far before a phase 2 trial set up - hold

User Image GABBYGIRL Posted - 4 days ago

$TLSA

User Image AsiaMarket Posted - 4 days ago

$TLSA Just a bit of a tree shake, cleared out the loose hands. Onwards and Upwards

User Image rp6577 Posted - 4 days ago

$TLSA dip will get bought

Analyst Ratings
ThinkEquity Buy Jun 13, 22